SCHEMBL31224883

SCHEMBL31224883

CC(C)(C)OC(=O)N1CCOCC1c1cc(Cl)nc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MALT1 Q9UDY8 1/20 0.44
▸ USP2 O75604 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CCNC P24863 1/20 0.38
▸ CDK8 P49336 1/20 0.38
▸ TSHR P16473 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ RECQL P46063 1/20 0.36
▸ GRM5 P41594 1/20 0.36
▸ OPRK1 P41145 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.35
▸ HSP90AB1 P08238 1/20 0.35
▸ NR1H2 P55055 2/20 0.35
▸ NR1H3 Q13133 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26639088 0.84 GRM5 (0.41) TSHRLMNAMEN1MAPTHTT
SCHEMBL30855098 0.83 MALT1 (0.39) MALT1USP2SMN1; SMN2CCNCCDK8
SCHEMBL29333856 0.83 MALT1 (0.39) MALT1USP2SMN1; SMN2CCNCCDK8
SCHEMBL29333998 0.83 MALT1 (0.39) MALT1USP2SMN1; SMN2CCNCCDK8
SCHEMBL29333833 0.83 MALT1 (0.39) MALT1USP2SMN1; SMN2CCNCCDK8
SCHEMBL29333842 0.82 USP2 (0.39) MALT1USP2SMN1; SMN2CCNCCDK8
SCHEMBL29333969 0.81 MALT1 (0.38) MALT1USP2SMN1; SMN2CCNCCDK8
SCHEMBL31224305 0.81 MALT1 (0.40) MALT1PIK3R1PIK3CA
SCHEMBL29333891 0.81 MALT1 (0.37) MALT1CCNCCDK8TSHRLMNA
SCHEMBL29334145 0.80 GRM5 (0.39) MALT1USP2SMN1; SMN2CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024259171-A9 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2025-01-23 — — WO disclosed
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2025-01-09 — — US disclosed
WO-2024259171-A2 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF KEAP1, NFE2L2, NQO1 MALT1 4607/4885USP2 588/4885SMN1; SMN2 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback